Drug Database
LE
levocetirizine + pseudoephedrine (HCP 0703 / Cossac L / HCP0703)
✓ ApprovedHanmi Pharmaceutical · HRH1 · Small Molecule
What is levocetirizine + pseudoephedrine?
levocetirizine + pseudoephedrine is a small molecule developed by Hanmi Pharmaceutical. It is approved for therapeutic indications via oral (po).
Drug Profile
| Brand Names | HCP 0703, Cossac L, HCP0703 |
| Company | Hanmi Pharmaceutical |
| Drug Class | Small Molecule |
| Molecular Target | HRH1 |
| Route | Oral (PO) |
| Status | Approved |
Sources: ClinicalTrials.gov, Hanmi Pharmaceutical
Mechanism of Action
Molecular Targets
levocetirizine + pseudoephedrine acts on 1 molecular target:
| HRH1 | histamine receptor H1 (HH1R, H1R) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Therapeutic Indications
levocetirizine + pseudoephedrine is developed for 1 unique indication across 1 therapeutic area.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Respiratory, thoracic and mediastinal disorders | Rhinitis allergic | ✓ Approved |
Related Research Articles
Unable to load articles right now.